70 patents
Utility
Anti-viral Compounds
18 Jan 24
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
Filed: 5 Jul 23
Utility
Bicyclic pyridazinones and methods of use thereof
2 Jan 24
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B
19 Dec 23
Sandrine Vendeville, Yannick Debing, Antitsa Dimitrova Stoycheva, Pierre Jean-Marie Bernard Raboisson
Filed: 13 Oct 21
Utility
Modulators of THR-β and methods of use thereof
12 Dec 23
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
Filed: 8 Jul 21
Utility
Pyrrole Compounds
7 Dec 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit
Filed: 22 Aug 23
Utility
Modified Gapmer Oligomers and Methods of Use Thereof
30 Nov 23
The disclosure includes antisense oligonucleotides (ASOs), including gapmer ASOs, and methods of making and using the same.
Leonid Beigelman, Vivek Kumar Rajwanshi, Laxman Eltepu, Saul Martinez Montero, Jin Hong
Filed: 16 Mar 23
Utility
Bicyclic Compounds
30 Nov 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David McGowan, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 17 Jul 23
Utility
Bicyclic Compounds
23 Nov 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David McGowan, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 18 Apr 23
Utility
Tricyclic compounds
21 Nov 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 22 Nov 21
Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
16 Nov 23
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 28 Jul 23
Utility
Oxindoles and methods of use thereof
24 Oct 23
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
19 Oct 23
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 29 Nov 22
Utility
2-pyridones and methods of use thereof
17 Oct 23
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21
Utility
Modified cyclic dinucleoside compounds as sting modulators
17 Oct 23
Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Leonid Beigelman, Santhosh Kumar Thatikonda, Antitsa Dimitrova Stoycheva
Filed: 6 May 20
Utility
Pyrrole compounds
3 Oct 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany
Filed: 16 Nov 21
Utility
Methods and compositions for targeting PD-L1
19 Sep 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
Filed: 12 Aug 21
Utility
Methods and compositions for targeting PD-L1
19 Sep 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
Filed: 19 May 21
Utility
MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF
25 May 23
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 7 Sep 22
Utility
Anti-viral Compounds
4 May 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Dorothée Alice Marie-Eve Bardiot, Koen Vandyck, Sandro Boland, Antitsa Dimitrova Stoycheva, Arnaud Didier Marie Marchand, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman
Filed: 14 Sep 22
Utility
Methods of reducing virus molecule levels
28 Mar 23
Methods of reducing levels of virus molecules and/or treating viral infections include contacting cells with an oligonucleotide inhibitor that targets a cellular host factor that is a target RNA or target protein involved in viral replication.
Chia-Cheng Kao, Lawrence M. Blatt, Leonid Beigelman
Filed: 6 Nov 20